Erratum: The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study) (Journal Thrombosis Thrombolysis) (10.1007/s11239-009-0326-2));The pharmacodynamics of enoxaparin in percutaneous coronary intervention with precise rapid enoxaparin loading (PEPCI-PRE study)

Journal of Thrombosis and Thrombolysis

Volumn 28, Issue 2, 2009, Pages 224-228

  Martin, Jack L ^a   Fry, Edward T A ^b   Martin, Todd ^c   Atherley, Trevor H ^d   Martin, Seth S ^e   Slepian, Marvin J ^f  

^a BRYN MAWR HOSPITAL   (United States)

^b ST VINCENT HOSPITAL   (United States)

^c LANKENAU HOSPITAL   (United States)

^d NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

Acute coronary syndromes; Anti Xa levels; Early invasive management; Low molecular weight heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SINGLE DRUG DOSE;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 67949109552     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0337-z     Document Type: Erratum

References (22)

1. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F (1977) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group. N Engl J Med 337:447-452. doi: 10.1056/NEJM199708143370702
2. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100:1593-1601
3. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon JL, Guneri S, Jiang F, White HD, Kox KAA, Braunwald E (2006) Enoxaparin verus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:1477-1488. doi: 10.1056/NEJMoa060898
4. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31-41. doi: 10.1159/000180580
5. FRISC investigators (1999) Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Fragmin and fast revascularisation during InStability in coronary artery disease. Lancet 354:708-715. doi: 10.1016/ S0140-6736(99)07349-3
6. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E (2001) TACTICS (treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy) - thrombolysis in myocardial infarction 18 investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344:1879-1887. doi: 10.1056/NEJM200106213442501
7. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, Wheatley DJ, Pocock SJ (2002) Randomized intervention trial of unstable angina investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: The British Heart Foundation RITA 3 randomized trial randomized intervention trial of unstable angina. Lancet 360:743-751. doi: 10.1016/S0140-6736(02)09894-X
8. Fintel DJ, Ledley GS et al (2000) Management of patients with non-ST-segment elevation acute coronary syndromes: Insights from the PURSUIT trial. Clin Cardiol 23(Suppl 5):V1-V12
9. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WEII, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 guidelines for the management of patients with unstable angina/Non-ST-elevation myocardial infarction). Circulation 116:e148-e304. doi: 10.1161/CIRCULATIONAHA.107.737312
10. Gibson CM, Murphy SA, Montalescot G, Morrow DA, Diego A, Cohen M, Gulba DC, Kracoff OH, Lewis BS, Roguin N, Antmann EM, Braunwald E, for the ExTRACT-TIMI 25 Investigators (2007) Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49:2238-2246. doi: 10.1016/ j.jacc.2007.01.093
11. Khoobiar S, Mejevoi N, Kaid K, Boianqiu C, Setty S, Khalid K, Cohen M (2008) Primary percutaneous coronary intervention for ST-elevation myocardial infarction using an intravenous and subcutaneous enoxaparin low molecular weight heparin regimen. J Thromb Thrombolysis 26(2):85-90. doi: 10.1007/s11239-008-0258-2
12. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H (2004) SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA 292:45-54. doi: 10.1001/jama.292.1.45
13. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, Sotirov I, Thomas D (2001) Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 103:658-663
14. Montalescot G, Collet JP, Tanguy ML, Ankri A, Payot L, Dumaine R, Choussat R, Beygui F, Gallois V, Thomas D (2004) Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110:392-398. doi: 10.1161/ 01.CIR.0000136830.65073.C7
15. Kereiakes DJ, Grines C, Fry E, Esente P, Hoppensteadt D, Midei M, Barr L, Matthai W, Todd M, Broderick T, Rubinstein R, Fareed J, Santoian E, Neiderman A, Brodie B, Zidar J, Ferguson JJ, Cohen M (2001) NICE 1 and NICE 4 investigators. National investigators collaborating on enoxaparin. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary interventio. J Invasive Cardiol 13:272-278
16. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PEG, Bode C, Chiariello M, King SB, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR, STEEPLE Investigators (2006) Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355:1006-1017. doi: 10.1056/NEJMoa052711
17. Martin JL, Fry ET, Sanderink GJ, Atherley TH, Guimart CM, Chevalier PJ, Ozoux ML, Pensyl CE, Bigonzi F (2004) Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 61:163-170. doi: 10.1002/ccd.10726
18. Montalescot G, Cohen M, Salette G, Desmet J, Macaya C, Aylward PEG, Steg G, White HD, Gallo R, Steinhub SR (2008) Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous intervention: Insights from the STEEPLE trial. Eur Heart J 29:462-471. doi: 10.1093/eurheartj/ehn008
19. Welsh RC, Gordon P, Westerhout CM, Buller CE, O'Neill B, Armstrong PW (2007) A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: A WEST sub-study. Catheter Cardiovasc Interv Sep 70(3):341-348
20. Bijsterveld NR, Moons AH, Meijers JC, Levi M, Buller HR, Peters RJ (2003) The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes. J Am Coll Cardiol 42:424-427. doi: 10.1016/S0735-1097(03)00653-3
21. Levine GN, Ferrando T (2004) Degree of anticoagulation after one subcutaneous and one subsequent intravenous booster dose of enoxaparin: implications for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. J Thromb Thrombolysis 17:167-171. doi: 10.1023/B:THRO.0000040484.99422.77
22. Zalc S, Lemos PA, Esteves A, Ribeiro EE, Horta P, Nicolau JC, Ramires JA, Cohen M, Martinez EE (2006) Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low molecular weight heparin enoxaparin. J Invasive Cardiol 18(2):45-48